Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|9|4|510-518

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.9, Iss.4, 2009-06, pp. : 510-518

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples

By di Iasio Maria  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1761-1765

Springer Publishing Company

Access to resources Recommend Favorite

Nanoparticles Loaded with Nutlin-3 Display Cytotoxicity Towards p53 wild–type JVM-2 But Not Towards p53 mutated BJAB Leukemic Cells

By  

Current Medicinal Chemistry, Vol. 20, Iss. 21, 2013-07 ,pp. : 2712-2722

Bentham Science Publishers

Access to resources Recommend Favorite

Synergistic Cytotoxic Activity of Recombinant TRAIL Plus the Non-Genotoxic Activator of the p53 Pathway Nutlin-3 in Acute Myeloid Leukemia Cells

By  

Current Drug Metabolism, Vol. 8, Iss. 4, 2007-05 ,pp. : 395-403

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in the Therapeutic Perspectives of Nutlin-3

By  

Current Pharmaceutical Design, Vol. 17, Iss. 6, 2011-02 ,pp. : 569-577

Bentham Science Publishers

Access to resources Recommend Favorite

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment

By  

Mini Reviews in Medicinal Chemistry, Vol. 18, Iss. 2, 2018-01 ,pp. : 173-183

Bentham Science Publishers

Access to resources Recommend Favorite